Melanie Thistle joined CND Life Sciences as Senior Vice President, Commercial in early 2026 and brings 30 years of U.S. and international commercial strategy and leadership experience across biotechnology, precision medicine, diagnostics, and other high-growth innovation companies.
Melanie’s career has centered on building and leading commercial organizations at key inflection points in healthcare innovation. She began her professional career in entrepreneurial technology companies, spending nearly a decade helping Fortune 200 executives prepare for the early digital transformation era and later supporting physicians through the adoption of electronic prescribing technologies.
She then spent nearly a decade at Genzyme Corporation, where she built and led multiple commercial functions including sales, marketing, training and development, U.S. and international product launches, and integration of acquired businesses into scaled commercial models.
Over the past decade, Melanie held leadership roles at Genomic Health and Exact Sciences, contributing to the growth of precision oncology and cancer screening businesses during a period in which the organization advanced multi-cancer early detection and minimal residual disease strategies. Her experience spans enterprise commercial strategy and execution, health policy and government affairs, reimbursement strategy, and building high performing teams in complex and evolving markets.
At CND Life Sciences, Melanie leads the company’s commercial organization with direct oversight of Sales, Marketing, Clinical Services, Customer Call Center, Field Training, and elements of Patient Access. She is focused on strengthening commercial execution and advancing timely and more precise diagnosis of neurodegenerative disease.
A former collegiate athlete, Melanie earned her bachelor’s degree from Regis College and her MBA with honors from Suffolk University. Outside of work, she enjoys staying active and spending time with her husband, son, and golden retriever.
